Tactile Systems Stock Price, News & Analysis

Tactile Systems Technology (Nasdaq:TCMD), a medical technology company, announced participation in the Piper Sandler 34th Annual Healthcare Conference. The event will take place at the Lotte New York Palace on November 30, 2022, with a fireside chat scheduled for 1:30 p.m. Eastern Time. Investors can access a live audio webcast of the presentation on the company’s investor relations website, along with a replay following the event.

The company focuses on developing at-home therapies for chronic conditions like lymphedema, enhancing patient care and reducing healthcare costs.

Tactile Systems Technology, Inc. (Nasdaq: TCMD) reported a 24% year-over-year increase in third quarter revenue to $65.3 million, up from $52.5 million. This revenue included $11.0 million from airway clearance products, largely due to the AffloVest acquisition. Despite a net loss of $2.3 million, improved profitability metrics were noted, with non-GAAP net income of $1.9 million. The company raised its full-year revenue guidance to $242 million to $245 million, reflecting ongoing growth and strong demand in their DME channel.

Tactile Systems Technology (Nasdaq:TCMD) announced that it will release its third quarter 2022 financial results on November 7, 2022, after market close. A conference call will follow at 5:00 p.m. ET for an in-depth discussion of the results. Interested participants can join by dialing 877-407-3088 (international callers: 201-389-0927) with access code 13733034. The call will also be available via a live webcast on the company’s investor relations website. Tactile Medical focuses on developing at-home therapies for chronic conditions, improving patient care and reducing healthcare costs.

Tactile Systems Technology (Nasdaq: TCMD) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York City. The company's management will engage in a fireside chat on September 13 at 11:10 a.m. Eastern Time. Interested parties can access a live audio webcast through the company’s investor relations website, with an archive available for replay post-conference. Tactile Medical focuses on at-home therapies for chronic conditions like lymphedema and chronic pulmonary disease.

Tactile Systems Technology (TCMD) reported a 17% year-over-year revenue increase for Q2 2022, totaling $59.6 million. This growth was driven primarily by airway clearance product sales, which rose 96% from the previous year. Despite revenue growth, the company faced a net loss of $4.6 million compared to a net income of $1.3 million in Q2 2021, and operating expenses increased by 30%. The updated revenue guidance for 2022 is now set between $238 million and $242 million, reflecting an expected 14% to 16% growth.

Tactile Systems Technology (Nasdaq: TCMD) has announced the full market release of its new ComfortEase garments, enhancing the Flexitouch Plus system for lymphedema management. Developed from over 18,000 patient and therapist feedback, these garments aim to improve comfort, fit, and usability. Additionally, the company introduced the Kylee mobile app, assisting patients in health monitoring and symptom management. The app enables users to track their progress and engage with healthcare providers, reinforcing Tactile Medical's commitment to supporting patients with chronic conditions.

Tactile Systems Technology (Nasdaq: TCMD) will release its Q2 2022 financial results on August 1, 2022, after market close. The company specializes in medical devices for chronic diseases, providing at-home therapies for conditions like lymphedema and chronic venous insufficiency. A conference call will follow at 5:00 PM ET for discussion and a Q&A session. Interested parties can join by calling 877-407-3088 or via a live webcast on the investor relations website.

Tactile Systems Technology (Nasdaq: TCMD) announced a consensus statement highlighting the treatment of lymphedema, particularly secondary to chronic venous insufficiency (CVI). Published in Phlebology: The Journal of Venous Disease, the statement received endorsements from three independent professional societies. Key points include that pneumatic compression is recommended for lymphedema patients, and 92% of experts support its use. CEO Dan Reuvers emphasized the importance of addressing the estimated 20 million undiagnosed lymphedema cases in the U.S.

Tactile Systems Technology (Nasdaq: TCMD) will participate in the William Blair 42nd Annual Growth Stock Conference from June 6-9, 2022, at the Loews Chicago Hotel. Management will present to investors on June 7 at 1:20 p.m. Central Time, followed by a breakout session. A live audio webcast will be available on the company’s investor relations website, with a replay accessible after the conference.

Tactile Medical specializes in developing at-home therapies for chronic conditions like lymphedema and chronic pulmonary disease, aiming to improve patient care and reduce healthcare costs.